Allotera raises $35M as off-the-shelf CAR-T reaches pivotal stage
Allotera’s new financing supports an allogeneic CAR-T programme that has moved into global pivotal development.
Off-the-shelf cell therapy is moving from platform promise toward later-stage clinical execution.
What happened
Allotera Therapeutics, formerly Wugen, closed $35M in equity and venture debt.
The financing brings total capital associated with its Series C to $150M.
The company is advancing Sofi-cel, an allogeneic, off-the-shelf CD7-targeted CAR-T therapy, through a global pivotal study in relapsed or refractory T-cell cancers.
Why it matters
Traditional CAR-T manufacturing is highly personalised and operationally complex.
Allotera is pursuing a healthy-donor-derived approach that could simplify availability and manufacturing if the therapy proves effective.
The key signal is maturity: the programme has moved beyond a platform thesis into pivotal-stage clinical development.
The bigger picture
Cell therapy is trying to become more scalable.
The next generation of companies is competing not only on biological efficacy, but on whether manufacturing and distribution can support broader use. Allotera’s financing reflects that transition.